TY - JOUR
T1 - Human bullous pemphigoid antigen 2 transgenic skin elicits specific IgG in wild-type mice
AU - Olasz, Edit B.
AU - Roh, Jooyoung
AU - Yee, Carole L.
AU - Arita, Ken
AU - Akiyama, Masashi
AU - Shimizu, Hiroshi
AU - Vogel, Jonathan C.
AU - Yancey, Kim B.
N1 - Funding Information:
This work was supported in part by NIH Grant RO1 AR048982 to KBY.
PY - 2007/12
Y1 - 2007/12
N2 - Bullous pemphigoid antigen 2 (BPAG2) is targeted by autoantibodies in patients with bullous pemphigoid (BP), and absent in patients with one type of epidermolysis bullosa (OMIM #226650). A keratin 14 promoter construct was used to produce transgenic (Tg) mice appropriately expressing human BPAG2 (hBPAG2) in murine epidermal basement membrane (BM). Grafts of Tg skin placed on gender-matched, syngeneic wild type (Wt) or major histocompatibility complex I (MHC I)-/- mice elicited IgG that bound human epidermal BM and BPAG2. Production of such IgG in grafted mice was prompt (detectable within 16±2 days), robust (titer ≥1,280), durable (present ≥380 days), and correlated with the involution and loss of Tg skin grafts. MHC II-/- mice grafted with Tg skin did not develop anti-hBPAG2 IgG or graft loss indicating that MHC II:CD4+ T cell interactions were crucial for these responses. Tg skin grafts on Wt mice developed neutrophil-rich infiltrates, dermal edema, subepidermal blisters, and deposits of immunoreactants in epidermal BM. This model shows fidelity to alterations seen in patients with BP, has relevance to immune responses that may arise in patients with epidermolysis bullosa following BPAG2 gene replacement, and can be used to identify interventions that may block production of IgG against proteins in epidermal BM.
AB - Bullous pemphigoid antigen 2 (BPAG2) is targeted by autoantibodies in patients with bullous pemphigoid (BP), and absent in patients with one type of epidermolysis bullosa (OMIM #226650). A keratin 14 promoter construct was used to produce transgenic (Tg) mice appropriately expressing human BPAG2 (hBPAG2) in murine epidermal basement membrane (BM). Grafts of Tg skin placed on gender-matched, syngeneic wild type (Wt) or major histocompatibility complex I (MHC I)-/- mice elicited IgG that bound human epidermal BM and BPAG2. Production of such IgG in grafted mice was prompt (detectable within 16±2 days), robust (titer ≥1,280), durable (present ≥380 days), and correlated with the involution and loss of Tg skin grafts. MHC II-/- mice grafted with Tg skin did not develop anti-hBPAG2 IgG or graft loss indicating that MHC II:CD4+ T cell interactions were crucial for these responses. Tg skin grafts on Wt mice developed neutrophil-rich infiltrates, dermal edema, subepidermal blisters, and deposits of immunoreactants in epidermal BM. This model shows fidelity to alterations seen in patients with BP, has relevance to immune responses that may arise in patients with epidermolysis bullosa following BPAG2 gene replacement, and can be used to identify interventions that may block production of IgG against proteins in epidermal BM.
UR - http://www.scopus.com/inward/record.url?scp=36248972519&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=36248972519&partnerID=8YFLogxK
U2 - 10.1038/sj.jid.5700970
DO - 10.1038/sj.jid.5700970
M3 - Article
C2 - 17657247
AN - SCOPUS:36248972519
SN - 0022-202X
VL - 127
SP - 2807
EP - 2817
JO - Journal of Investigative Dermatology
JF - Journal of Investigative Dermatology
IS - 12
ER -